Prophylactic Effect of Mitomycin C and Bacillus Calmette-Guerin in Stage T1 of the Superficial Bladder Cancer.
- Author:
Ki Woon SON
1
;
Hyeon Su KIM
;
Tae Hee OH
Author Information
1. Department of Urology, University of Sung Kyun Kwan, College of Medicine, Masan Samsung Hospital, Masan, Korea.
- Publication Type:Original Article
- Keywords:
Intravesical instillation;
Mitomycin C;
BCG;
Superficial bladder tumor
- MeSH:
Administration, Intravesical;
Bacillus*;
Cystitis;
Follow-Up Studies;
Hematuria;
Humans;
Mitomycin*;
Mycobacterium bovis;
Recurrence;
Sodium;
Sodium Chloride;
Urinary Bladder Neoplasms*;
Urinary Bladder*
- From:Korean Journal of Urology
1997;38(9):957-962
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
We compared the efficacy and toxicity of mitomycin C and Bacillus Calmette-Guerin (BCG) intravesical instillation in 86 patients with stage T1 of the superficial bladder tumor. Of them, 34 patients were received mitomycin C (40 mg/40 ml sodium chloride, once a week for 8 weeks) and 26 patients were received BCG (120 mg/50 ml sodium chlorids, once a week for 6 weeks) after transurethrat resection of bladder tumor and 24 patients (control) underwent transurethral resection alone. The mean follow up period was 24.8 months in control group, 26.8 months in mitomycin C group and 25.7 months in BCG group. The mean time to recur was 11.3 months in control group, 11.5 months in mitomcyin C group and 15.9 in BCG group but there was no significant difference among each groups (p>0.05). The overall recurrence rate was 34.6% in BCG group compared with 70.5% in mitomycin C group and 75.0% in control group, showing significant difference (p<0.05). Side effects were more common after BCG instillation than mitomycin C instillation. The most common side effect after BCG instillation was hematuria in 14 patients (53.8%). That of mitomycin C was cystitis in 10 patients (29.4%). Our study suggests that the prophylactic efficacy of BCG was significantly superior to that of mitomycin C, but there was no significant superiority regarding prophylactic effect of reduced mean time to recur in stage T1 bladder cancer patients. Additionally, further follow up studies were needed in mitomycln C.
